# Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

> **NCT01830816** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Multiple Myeloma
- Advanced Solid Tumors

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT01830816
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-16
- **Primary completion:** 2015-03-03
- **Final completion:** 2016-11-18
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830816, "Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01830816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*